Didactic Series. HIV Drug-Drug Interactions: OTC and non-prescription medications. Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015

Similar documents
Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV Drugs and the HIV Lifecycle

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

Medication Errors Focus on the HIV-Infected Patient

The ART of Managing Drug-Drug Interactions in Patients with HIV

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012

HIV Management Update 2015

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Didactic Series. CROI 2014 Update. March 27, 2014

Simplifying HIV Treatment Now and in the Future

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

Interactions with Over the Counter Medications and Herbals

Antiretroviral Dosing in Renal Impairment

Pharmacological considerations on the use of ARVs in pregnancy

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Watch Out! Drug Drug Interactions with Antiretrovirals

Industry Data Request

Continuing Education for Pharmacy Technicians

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

Comprehensive Guideline Summary

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents

HIV medications HIV medication and schedule plan

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

Clinical Pharmacology of Integrase Inhibitors

ART and Prevention: What do we know?

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update

Criteria for Oral PrEP

Industry Request Integrase Inhibitors

ANTIRETROVIRAL TREATMENTS (Part 1of

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Actualización y Futuro en VIH

Cost impact of an HIV MDT for managing anti-retroviral switch

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

HIV for the Non-ID Pharmacist

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

The Hospitalized HIV+ Patient

Pediatric Antiretroviral Resistance Challenges

Occupational and Non- Occupational HIV Post-exposure Prophylaxis

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv

HIV Treatment: State of the Art 2013

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants

continuing education for pharmacists

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Didactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego

HIV associated CNS disease in the era of HAART

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

Drug Interactions. Together, we can change the course of the HIV epidemic one woman at a time.

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

Class Review: HIV Antiretroviral Agents

Guide to changing ART:

Central Nervous System Penetration of ARVs: Does it Matter?

HIV Treatment: New and Veteran Drugs Classes

ARVs in Development: Where do they fit?

INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study

Guide to changing treatment:

Drug-Drug Interactions that Matter

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

104 MMWR December 17, 2004

Treatment and Care: Product portfolio

Susan L. Koletar, MD

SELECTING THE BEST ART FOR EACH PATIENT

Updated Guidelines for Managing HIV/HCV Co-Infection

Approach for the Newly Diagnosed HIV Positive Patient

Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin

HIV Treatment Guidelines

STRIBILD (aka. The Quad Pill)

Summary of ARV prescribing guidelines in London

Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era

Friday afternoon Programme

1/13/16. Updated April 2015

Starting and Switching ART: 2016

Supplementary information

Exploring HIV in 2017: What a pharmacist needs to know

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

I S H P S p r i n g C o n f e r e n c e Megan Koyle, PharmD Elaine Nguyen, PharmD, MPH, BCPS

Transcription:

Didactic Series HIV Drug-Drug Interactions: OTC and non-prescription medications Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of California, San Diego School of Medicine designates this educational activity for a maximum of one credit per hour AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. 1

Learning Objectives 1) Counsel patients interested in using herbal supplements with antiretroviral regimens 2) Describe potential interactions between OTC GERD medications and antiretroviral regimens 3) Counsel patients regarding potential harms of recreational drug use and antiretroviral therapy. 2

Strategies to evaluate DDI OBTAIN complete medication history SEARCH for definite vs probable vs theoretical interactions Pharmacokinetic Pharmacodynamic ASSESS clinical significance of interactions MANAGE/MONITOR interaction EDUCATE patient 3

Pharmacodynamic Interactions Antagonism e.g. zidovudine, stavudine (d4t) Additive Toxicities e.g. methadone, citalopram: QT-Prolonging Agents Disease-Drug Interactions Anxiety/Insomnia and Efavirenz 4

Pharmacokinetic Interactions 5

Herbal Supplements Mechanism is primarily based on CYPP450-based interactions Garlic: Decreased saquinavir St. John s Wort: Decreases PI, NNRTI, INSTI (except raltegravir) Ginko Biloba: Case reports decreased efavirenz Grapefruit juice?? 6

Multivitamins Poll Question: What class of drugs have concerns regarding multivitamin drug interactions? NRTI NNRTI PI INSTI Maraviroc All of the above 7

Integrase Inhibitors & divalent cations Integrase inhibitors are subject to complex binding to polyvalent ions. Decreases serum levels of dolutegravir when co-administered with calcium supplements. Pt education: INSTI administered 2 hours before or 6 hours after medicines containing divalent cations. 8

Herbal & Vitamin Interactions References HIV-druginteractions.org Natural Standard (subscription) Pharmacists 9

GERD interactions 10

Antiretrovirals Prefer Acidic ph Atazanavir: including when boosted with ritonavir or cobicistat Rilpivirine Possibly other PI: fosamprenavir, nelfinavir, indinavir, saquinavir, timpranavir 11

Rilpivirine & GERD Management Contraindicated with PPI Limit dosing of H2-blockers to once/day: separate by at least 12 hours 12

Atazanavir & GERD Management Depends upon several HIV/ARV factors: With or without tenofovir Boosted or unboosted Treatment naive or experienced (resistant virus) Depends upon several GERD factors: Dose of PPI Dose of H2-blocker Timing of administration 13

Management Switch Protease Inhibitors Monitor during hospitalizations Counsel about OTC drug use 14

Recreational drug interactions 15

16

17

Learning Objectives 1) Counsel patients interested in using herbal supplements with antiretroviral regimens 2) Describe potential interactions between OTC GERD medications and antiretroviral regimens 3) Counsel patients regarding potential harms of recreational drug use and antiretroviral therapy. 18

Questions 19